Advanced Search
Therapeutic Area Disease
Title Drug Phase
Clinical Trials Listing
Active treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
SURG-073 A Randomized Controlled Trial of Perioperative Risk Stratification and Risk-based, Protocol-driven Management in Patients Undergoing Elective Major Cancer Surgery III Not Applicable
M12-914 A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without the Poly ADP-ribose Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic or Locally Advanced Unresectable Breast Cancer Gene (BRCA)-Associated Breast Cancer III Chemotherapy, PARP Inhibitor carboplatin; paclitaxel; veliparib
EA1131 A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Observation in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy III Chemotherapy carboplatin; cisplatin
1VIT14039 IRON CLAD: Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose Injection) III
BO27938 A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients With HER2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy III Immunotherapy (Monoclonal Antibody), Immunotherapy trastuzumab; ado-trastuzumab emtansine (T-DM1)
D081CC00006 A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy (OlympiA) III PARP Inhibitor olaparib
D0819C00003 A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations (OlympiAD) III Chemotherapy, PARP Inhibitor vinorelbine; capecitabine; eribulin mesylate; olaparib
NSABP-B-51/RTOG-1304 A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy III Radiation Therapy Not Applicable
AT005074 Long-Term Chamomile Therapy for Generalized Anxiety Disorder (GAD) III Supportive Care Not Applicable
UPCC-05912 Extended Duration Varenicline for Smoking Among Cancer Patients: A Clinical Trial III Other, Supportive Care varenicline tartrate
NRG-BR002 A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer II / III Radiation Therapy, Surgery Not Applicable
MO27775 A Randomized, Two-arm, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab Plus an Aromatase Inhibitor in First Line Patients With HER2-positive and Hormone Receptor-positive Advanced (Metastatic or Locally Advanced) Breast Cancer. II Chemotherapy, Hormonal Therapy, Immunotherapy (Monoclonal Antibody), Signal Transduction Inhibitor docetaxel; anastrozole; trastuzumab; pertuzumab; paclitaxel
NSABP FB-11 A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer II Hormonal Therapy, Signal Transduction Inhibitor letrozole; palbociclib
ECOG-E3108 A Phase II Prospective Trial Correlating Progression Free Survival With CYP2D6 Activity in Patients With Metastatic Breast Cancer Treated With Single Agent Tamoxifen II Hormonal Therapy tamoxifen
368255 Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence II Immunotherapy (Vaccine), Immunotherapy (Monoclonal Antibody) GM-CSF vaccine; trastuzumab;
RTOG-1119 Phase II Randomized Study of Whole Brain Radiotherapy in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer: A Collaborative Study of RTOG and KROG II Radiation Therapy, Signal Transduction Inhibitor lapatinib
J1365 Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors II Immunotherapy (Monoclonal Antibody), Signal Transduction Inhibitor pembrolizumab
ML28897 My Pathway: An Open Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib, and Vismodegib in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents II Immunotherapy (Monoclonal Antibody), Signal Transduction Inhibitor trastuzumab; erlotinib; pertuzumab; vemurafenib; vismodegib
CO-3810-025 A Phase 2, Randomized, Open-label, Multicenter, Safety and Efficacy Study of Oral Lucitanib in Patients With FGF Aberrant Metastatic Breast Cancer II Signal Transduction Inhibitor lucitanib
UPCC-10114 A Phase 2 Pilot Feasibility Study of Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive Invasive Breast Cancer II Hormonal Therapy, Signal Transduction Inhibitor anastrozole; exemestane; letrozole; palbociclib
UPCC 05114 A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer II Biological Therapy lurbinectedin
UPCC-04113 A FEASIBILITY AND PHASE II TRIAL OF ACCELERATED PARTIAL BREAST IRRADIATION USING PROTON THERAPY FOR WOMEN WITH STAGE IA-IIA BREAST CANCER II Radiation Therapy, Proton Therapy Not Applicable
12-258 A Randomized Phase II Trial of Neoadjuvant Cisplatin vs. Doxorubicin/Cyclophosphamide (AC) in Women With Newly Diagnosed Breast Cancer and Germline BrCa Mutations II Chemotherapy cisplatin; cyclophosphamide; doxorubicin
097517 I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2) II Chemotherapy, Immunotherapy (Monoclonal Antibody), Signal Transduction Inhibitor, PARP Inhibitor trastuzumab; pertuzumab; cyclophosphamide; paclitaxel; doxorubicin; neratinib; veliparib; figitumumab; trebananib; ganitumab; conatumumab; metformin ; ado-trastuzumab emtansine (T-DM1);
M12-895 A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer II Chemotherapy, PARP Inhibitor carboplatin; temozolomide; paclitaxel; veliparib
INCB 18424-268 A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer II Chemotherapy, Signal Transduction Inhibitor capecitabine; ruxolitinib
10-096 A Phase I/II Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors I / II Chemotherapy, Signal Transduction Inhibitor etoposide; vorinostat
13P.387 A Phase I/II Study of Romidepsin in Combination With Abraxane in Patients With Metastatic Inflammatory Breast Cancer I / II Chemotherapy, Signal Transduction Inhibitor nab-paclitaxel; romidepsin
C32496/1105 An Open-Label, Phase 1/Phase 2, Single-Agent Study of CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and in Patients With Advanced Melanoma and Metastatic Colorectal Cancer With BRAF Mutation in Phase 2 I / II Signal Transduction Inhibitor
INCB 24360-202 A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors (Phase 1) Followed by a Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Advanced NSCLC (Phase 2)(INCB 24360-202 / MK-3475-037 / KEYNOTE-037) I / II Immunotherapy (Monoclonal Antibody), Signal Transduction Inhibitor INCB024360; pembrolizumab
UPCC 03114 A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS I / II Immunotherapy trastuzumab; HER-2 pulsed DC1 vaccine
CD-ON-MEDI4736-1108 A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors I / II Immunotherapy (Monoclonal Antibody)
15252 A Phase 1b Study of LY2835219 in Combination With Endocrine Therapies for Patients With Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer I Hormonal Therapy, Signal Transduction Inhibitor anastrozole; tamoxifen; exemestane; letrozole; everolimus; abemaciclib
110060 A Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction I Signal Transduction Inhibitor belinostat
09-051 A Phase I Study of Stereotactic Body Radiation Therapy (SBRT) for Liver Metastases I Radiation Therapy Not Applicable
IMGN853-0401 A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors I Immunotherapy (Monoclonal Antibody)
CD-ON-MEDI3617-1043 A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617, a Fully Human Monoclonal Antibody Directed Against ANG2, in Adult Subjects With Advanced Solid Tumors I Immunotherapy (Monoclonal Antibody)
B2151002 A Phase 1B Open-Label Three-Arm Multi-Center Study To Assess The Safety And Tolerability Of PF-05212384 (PI3K/MTor Inhibitor) In Combination With Other Anti-Tumor Agents I Chemotherapy, Signal Transduction Inhibitor docetaxel; cisplatin; dacomitinib;
OER-RT-042 Phase I Study of Pulsed Low Dose Rate Reirradiation Delivered With 3DCRT/IMRT I Radiation Therapy Not Applicable
120066 Phase I Trial of Oral 5-Fluoro-2-Deoxycytidine With Oral Tetrahydrouridine in Patients With Advanced Solid Tumors I Signal Transduction Inhibitor 5-fluoro-2-deoxycytidine; tetrahydrouridine
12D.396 Pilot Study of Anti-oxidant Supplementation With N-Acetyl Cysteine in Stage 0/I Breast Cancer I Other n-acetylcysteine
UPCI-10-115 An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors I Chemotherapy, PARP Inhibitor carboplatin; paclitaxel; veliparib
C28001 An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion Phase in Patients With Metastatic Melanoma I Signal Transduction Inhibitor
11-091 PHASE I STUDY OF FRACTIONATED STEREOTACTIC RADIOSURGERY FOR LARGE BRAIN METASTASES I Radiation Therapy Not Applicable
UPCC 08913 A Pilot and Feasibility Study of Intraoperative Imagery of Solid Tumors With Indocyanine Green I Imaging Procedure Indocyanine Green
UPCC 13111 Clinical Trial of Autologous cMet Redirected T Cells Administered Intratumorally in Patients With Breast Cancer I Immunotherapy Autologous Tumor Cell Vaccine
UPCC 22913 Phase I Study of TERT DNA and Electroporation With and Without IL-12 DNA for Patients With Breast, Lung, or Pancreatic Cancer at High Risk of Relapse Post Definitive Surgery and Adjuvant Therapy I Immunotherapy Interleukin 12 (IL-12); INO-1400
UPCC 27914 A Phase 1 First-in-Human Dose Study of LY3023414 in Patients With Advanced Cancer I Biological Therapy, Chemotherapy, Hormonal Therapy letrozole; midazolam;
UPCC-02111 A Phase 1 Trial of PD-0332991 and Paclitaxel in Patients With Rb-Expressing Advanced Breast Cancer I Chemotherapy, Signal Transduction Inhibitor paclitaxel; palbociclib
818065 A Pilot & Feasibility Study of the Imaging Potential of EC17 in Subjects Undergoing Surgery Presenting Breast Cancer I Other
UPCC 25914 Pilot Trial of HER-2/Neu Pulsed DC1 Vaccine for Patients With HER-2 Positive I Immunotherapy (Vaccine) HER-2 pulsed DC1 vaccine
C28002 A Multiarm, Open-label, Phase 1b Study of MLN2480 (an Oral A-, B-, and CRAF Inhibitor) in Combination With MLN0128 (an Oral mTORC 1/2 Inhibitor), or Alisertib (an Oral Aurora A Kinase Inhibitor), or Paclitaxel, in Adult Patients With Advanced Nonhematologic Malignancies I Chemotherapy, Signal Transduction Inhibitor paclitaxel; alisertib; ;
PV-10-LC-01 A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Recurrent Hepatocellular Carcinoma I Chemotherapy PV-10
UPCC 25113 Pilot Phase I HER-2 Pulsed DC Vaccine To Prevent Recurrence For Patients With HER-2 Driven High Risk Invasive Breast Cancer I Immunotherapy (Vaccine) HER-2 pulsed DC1 vaccine
818561 Pilot Phase I HER-2 Pulsed DC Vaccine to Prevent Recurrence for Patients With HER-2 Driven High Risk Invasive Breast Cancer Post Neoadjuvant Chemotherapy I Immunotherapy (Vaccine) Dendritic Cell Vaccine
UPCC 26113 Pilot Phase I HER-2 Pulsed-DC Vaccine To Prevent Recurrence For Patients With HER-2 Driven High Risk Invasive Breast Cancer Post Neoadjuvant Chemotherapy I Immunotherapy (Vaccine) HER-2 pulsed DC1 vaccine
UPCC 30914 Choosing Options for Insomnia in Cancer Effectively (CHOICE): A Comparative Effectiveness Trial of Acupuncture and Cognitive Behavior Therapy 0 Complementary and Alternative Therapy Not Applicable
NCT01295658 Cancer Experience Registry Not Specified Not Applicable
PRO00000367 A Low-Carbohydrate Diet for Advanced or Metastatic Cancer Not Specified Other Not Applicable
12C.616 A Feasibility Pilot Trial Evaluating Caloric Restriction for Oncology Research in Early Stage Breast Cancer Patients Not Specified Radiation Therapy, Surgery Not Applicable
14D.272 Use of a Brief Mindful Meditation Practice in Adult Cancer Patients Receiving Radiation Therapy Not Specified Not Applicable
STUDY00000378 The Value of Integrating Visual Arts (VIVA): Evaluating the Benefits of Hospital Room Artwork on Inpatient Wellbeing Not Specified Not Applicable
W81XWH-12-1-0066 Quantitative Subharmonic Breast Imaging: Subharmonic Imaging and Pressure Estimation for Monitoring Neoadjuvant Chemotherapy Not Specified Procedure definity®
UPCC-12110 The Effects of Radiation Therapy on the Reconstructed Breast: An Evaluation Using MR Imaging Not Specified Radiation Therapy Not Applicable
UPCC-03111 A Study of hTERT/Survivin Multi-Peptide Vaccination With Basiliximab And Prevnar For Patients With Metastatic Breast Cancer Not Specified Immunotherapy (Monoclonal Antibody) basiliximab; prevnar
UPCC 08113 A Randomized Study of the Effect of Yoga in Patients With Breast Cancer Receiving Radiation Therapy Not Specified Complementary and Alternative Therapy Not Applicable
UPCC 17113 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET/CT) For The Evaluation Of Response To Therapy In Bone-Dominant Metastatic Breast Cancer Not Specified Imaging Procedure fludeoxyglucose F 18
ROG-SCCI 09-003-2 Enhancing Physical Activity Adherence After Breast Cancer Diagnosis (BEAT Cancer Study II) Not Specified Other Not Applicable
COMETI-P2-2012 COMETI Phase 2: Characterization of Circulating Tumor Cells From Subjects With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index Not Specified Other Not Applicable
UPCC-12807 Assessing Fertility Potential in Female Cancer Survivors Not Specified Imaging Procedure, Blood or Tissue Collection Not Applicable
PRO11020226 Acellular Dermal Matrix in Tissue Expander Breast Reconstruction: A Prospective, Randomized, Clinical Trial Comparing SurgiMend PRS and AlloDerm RTU IV Other Not Applicable
Active non-treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug

Sorry, your search did not return any Penn Non-Treatment Trials trials

Active advanced solid tumor trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug

Sorry, your search did not return any Phase 1: Solid Tumor Trials trials

Active proton therapy trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug

Sorry, your search did not return any Proton Therapy Trials trials

Request a call

A clinical trial navigator is available to help you search for clinical trials offered by the Penn Medicine Abramson Cancer Center. This is a confidential free service available Monday-Friday, 9:00am-5:00pm (ET). Requests are processed in the order they are received.



*
*
*
*

Please do not submit another person’s name or email without his or her consent.